title: Recalcitrant neovascular macular degeneration after anti-VEGF therapy: an ongoing challenge.
abstract: This editorial describes the challenge of managing eyes that demonstrate signs of persistent exudation after anti-VEGF treatment and illuminates the significance of a new report of using high-dose ranibizumab in treating recalcitrant neovascular age-related macular degeneration.
authors.forename: Carmen A
authors.initials: CA
authors.lastname: Puliafito
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D000069579:Ranibizumab; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab